US8338395 — Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Method of Use · Assigned to Bayer Intellectual Property GmbH · Expires 2027-05-08 · 1y remaining
What this patent protects
This patent protects methods for achieving prolonged, physiologically acceptable serum testosterone levels in patients deficient in endogenous testosterone.
USPTO Abstract
Described are methods for providing prolonged physiologically acceptable steady state serum testosterone levels in a patient deficient in endogenous testosterone levels, methods for male contraception and methods for treating a disease or symptom associated with deficient endogenous levels of testosterone in a man, by intramuscularly administering testosterone esters in a vehicle.
Drugs covered by this patent
- Aveed (TESTOSTERONE UNDECANOATE) · Marius
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1500 |
— | Aveed |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.